Bayer (BAYRY) Price & Analysis

Compare

2,084 Followers

BAYRY Stock Chart & Stats

$7.94

-$0.08(-1.46%)

At close: Jan 08 4:00 PM EST

$7.94

-$0.08(-1.46%)

Day’s Range― - ―

52-Week Range$4.89 - $10.69

Previous CloseN/A

Volume306.92K

Average Volume (3M)62.66K

Market Cap

$41.51B

Enterprise Value$67.40B

Total Cash (Recent Filing)$7.24B

Total Debt (Recent Filing)$46.57B

Price to Earnings (P/E)―

Beta0.45

Next Earnings

Mar 03, 2026

EPS Estimate

0.09

Next Dividend Ex-DateN/A

Dividend Yield0.3%

Share Statistics

EPS (TTM)0.17

Shares Outstanding3,929,696,000

10 Day Avg. Volume0

30 Day Avg. Volume62,665

Financial Highlights & Ratios

PEG Ratio0.56

Price to Book (P/B)0.58

Price to Sales (P/S)0.40

P/FCF Ratio4.03

Enterprise Value/Market Cap1.62

Enterprise Value/Revenue1.42

Enterprise Value/Gross Profit2.52

Enterprise Value/Ebitda11.05

Forecast

1Y Price Target

$12.00

Price Target Upside51.13% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bayer News

Bayer price target raised to EUR 41 from EUR 30.40 at Berenberg

Berenberg analyst Sebastian Bray raised the firm’s price target on Bayer (BAYRY) to EUR 41 from EUR 30.40...

8d ago

Bayer price target raised to EUR 40 from EUR 34 at HSBC

HSBC analyst Rajesh Kumar raised the firm’s price target on Bayer (BAYRY) to EUR 40 from EUR 34...

13d ago

Bayer upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Bayer (BAYRY) to Overweight from Neutral with a price target of EUR 50, up from EUR...

15d ago

Bayer initiates clinical trial with BAY 3401016

Bayer (BAYRY) announced initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with...

19d ago

Bayer says Gadoquatrane met primary, secondary endpoints in trial

Bayer (BAYRY) announced results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of...

20d ago

Bayer upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Thibault Boutherin upgraded Bayer (BAYRY) to Overweight from Equal Weight with a price target of...

20d ago

Bayer welcomes Solicitor General support for U.S. Supreme Court review

Bayer (BAYRY) said it is “pleased the Solicitor General supports U. S. Supreme Court review of the petition...

21d ago

Bayer starts SUNFLOWER study

Bayer (BAYRY) announced the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and...

21d ago

Bayer announces MEDRAD Centargo system secures 510(k) clearance

Bayer (BAYRY) announced that its MEDRAD Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food...

22d ago

Dare Bioscience announces return of rights to Oveprene

Dare Bioscience (DARE) announced that all rights to Ovaprene, the company’s first-in-category, investigational, hormone-free monthly intravaginal contraceptive, will...

22d ago

DARE

Bayer Backs AskBio Gene Therapy Push in Pompe Disease: Early Trial Update and Investor Takeaways

Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Study Overview The PROGRESS-GT LOPD trial is...

4d ago

BAYRY

Bayer AG Earnings Call: Growth Amid Challenges

Bayer AG (($BAYRY)) has held its Q3 earnings call. Read on for the main highlights of the call....

1M ago

Is BAYRY a Buy, Before Earnings?

Bayer AG (BAYRY) is scheduled to report 3rd quarter earnings on 11/12/2025, before the market opens. Regarding Q3...

1M ago

Bayer’s New Study on Mirena: A Potential Game-Changer for Endometrial Hyperplasia Treatment

Bayer AG (($BAYRY)) announced an update on their ongoing clinical study. Bayer AG is launching a new clinical...

2M ago

BAYRY

BAYRY FAQ

What was Bayer AG’s price range in the past 12 months?

Bayer AG lowest stock price was $4.88 and its highest was $10.69 in the past 12 months.

What is Bayer AG’s market cap?

Bayer AG’s market cap is $41.51B.

When is Bayer AG’s upcoming earnings report date?

Bayer AG’s upcoming earnings report date is Mar 03, 2026 which is in 70 days.

How were Bayer AG’s earnings last quarter?

Bayer AG released its earnings results on Nov 12, 2025. The company reported $0.165 earnings per share for the quarter, beating the consensus estimate of $0.106 by $0.059.

Is Bayer AG overvalued?

According to Wall Street analysts Bayer AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bayer AG pay dividends?

Bayer AG pays a Annually dividend of $0.031 which represents an annual dividend yield of 0.3%. See more information on Bayer AG dividends here

What is Bayer AG’s EPS estimate?

Bayer AG’s EPS estimate is 0.09.

How many shares outstanding does Bayer AG have?

Bayer AG has 3,929,696,000 shares outstanding.

What happened to Bayer AG’s price movement after its last earnings report?

Bayer AG reported an EPS of $0.165 in its last earnings report, beating expectations of $0.106. Following the earnings report the stock price went up 5.912%.

Which hedge fund is a major shareholder of Bayer AG?

Currently, no hedge funds are holding shares in BAYRY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bayer Stock Smart Score

Neutral

Fundamentals

Return on Equity

-0.99%

Trailing 12-Months

Asset Growth

2.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bayer AG

Bayer AG is a global life sciences company headquartered in Leverkusen, Germany, operating primarily in the pharmaceuticals, consumer health, crop science, and animal health sectors. The company focuses on innovative solutions in healthcare and agriculture, producing a wide range of products including prescription medications, over-the-counter health products, agricultural chemicals, and biotechnology solutions aimed at improving crop yields and sustainability.

Bayer (BAYRY) Earnings & Revenues

Historic Earnings Reports

BAYRY Company Deck

BAYRY Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong growth in the Pharmaceuticals division and successful product launches, but it also addressed significant financial challenges, litigation risks, and market difficulties in Consumer Health.View all BAYRY earnings summaries

BAYRY Stock 12 Month Forecast

Average Price Target

$12.00

▲(51.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","8":"$8","13":"$13","5.5":"$5.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.5,8,10.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,9.10153846153846,9.343076923076923,9.584615384615384,9.826153846153845,10.067692307692308,10.30923076923077,10.55076923076923,10.792307692307691,11.033846153846154,11.275384615384615,11.516923076923078,11.758461538461539,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,9.10153846153846,9.343076923076923,9.584615384615384,9.826153846153845,10.067692307692308,10.30923076923077,10.55076923076923,10.792307692307691,11.033846153846154,11.275384615384615,11.516923076923078,11.758461538461539,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,9.10153846153846,9.343076923076923,9.584615384615384,9.826153846153845,10.067692307692308,10.30923076923077,10.55076923076923,10.792307692307691,11.033846153846154,11.275384615384615,11.516923076923078,11.758461538461539,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.33,"date":1704067200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.78,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.98,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.12,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.78,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >